JP2022552949A - キメラサイトカイン受容体 - Google Patents

キメラサイトカイン受容体 Download PDF

Info

Publication number
JP2022552949A
JP2022552949A JP2022521201A JP2022521201A JP2022552949A JP 2022552949 A JP2022552949 A JP 2022552949A JP 2022521201 A JP2022521201 A JP 2022521201A JP 2022521201 A JP2022521201 A JP 2022521201A JP 2022552949 A JP2022552949 A JP 2022552949A
Authority
JP
Japan
Prior art keywords
cells
optionally
seq
csfr
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022521201A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022552949A5 (https=
Inventor
ブラッド ネルソン
ミーガン フラー
マーティン ジェイ． ブーランジェ
Original Assignee
プロヴィンシャル ヘルス サービシーズ オーソリティ
ユーヴィック インダストリー パートナーシップス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロヴィンシャル ヘルス サービシーズ オーソリティ, ユーヴィック インダストリー パートナーシップス インコーポレイテッド filed Critical プロヴィンシャル ヘルス サービシーズ オーソリティ
Publication of JP2022552949A publication Critical patent/JP2022552949A/ja
Publication of JP2022552949A5 publication Critical patent/JP2022552949A5/ja
Priority to JP2025131121A priority Critical patent/JP2025163198A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4216—Receptors for colony stimulating factors [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4217—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/21—Transmembrane domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/22—Intracellular domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
JP2022521201A 2019-10-08 2020-10-08 キメラサイトカイン受容体 Pending JP2022552949A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025131121A JP2025163198A (ja) 2019-10-08 2025-08-06 キメラサイトカイン受容体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962912223P 2019-10-08 2019-10-08
US62/912,223 2019-10-08
PCT/CA2020/051346 WO2021068068A1 (en) 2019-10-08 2020-10-08 Chimeric cytokine receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025131121A Division JP2025163198A (ja) 2019-10-08 2025-08-06 キメラサイトカイン受容体

Publications (2)

Publication Number Publication Date
JP2022552949A true JP2022552949A (ja) 2022-12-21
JP2022552949A5 JP2022552949A5 (https=) 2023-10-16

Family

ID=75436949

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022521201A Pending JP2022552949A (ja) 2019-10-08 2020-10-08 キメラサイトカイン受容体
JP2025131121A Pending JP2025163198A (ja) 2019-10-08 2025-08-06 キメラサイトカイン受容体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025131121A Pending JP2025163198A (ja) 2019-10-08 2025-08-06 キメラサイトカイン受容体

Country Status (11)

Country Link
US (1) US20240122979A1 (https=)
EP (1) EP4041893A4 (https=)
JP (2) JP2022552949A (https=)
KR (1) KR20220108768A (https=)
CN (1) CN114929752A (https=)
AU (1) AU2020362554A1 (https=)
BR (1) BR112022006782A2 (https=)
CA (1) CA3151472A1 (https=)
IL (1) IL291282A (https=)
MX (1) MX2022003885A (https=)
WO (1) WO2021068068A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022254143A1 (en) * 2021-04-07 2023-11-23 Provincial Health Services Authority Modified granulocyte colony-stimulating factor (g-csf) and chimeric cytokine receptors binding same
WO2023192948A1 (en) * 2022-04-01 2023-10-05 Seattle Children's Hospital (dba Seattle Children's Research Institute) Chimeric cytokine receptors
CA3259305A1 (en) * 2022-07-11 2024-01-18 Sonoma Biotherapeutics, Inc. RECOMBINANT CYTOKINE RECEPTORS AND METHODS OF USE
JP2025529913A (ja) * 2022-08-26 2025-09-09 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー キメラサイトカイン受容体及び使用方法
IL322949A (en) 2023-03-03 2025-10-01 Arsenal Biosciences Inc Systems targeting PSMA and CA9
WO2026055342A1 (en) * 2024-09-04 2026-03-12 Arsenal Biosciences, Inc. Synthetic pathway activators
CN119912588B (zh) * 2025-04-01 2025-08-12 浙江大学 嵌合抗原受体、人诱导多能干细胞、髓系前体细胞样巨噬细胞及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08511000A (ja) * 1993-04-06 1996-11-19 フレッド ハッチンソン キャンサー リサーチ センター リンパ球におけるキメラサイトカインレセプター
JP2001501444A (ja) * 1995-11-27 2001-02-06 ミレニウム ファーマシューティカルズ インク． Ｏｂ受容体ならびに体重障害の診断および治療の方法
WO2006115026A1 (ja) * 2005-04-22 2006-11-02 Japan Science And Technology Agency ヒューマニン受容体又はヒュ－マニン様ポリペプチド受容体
US20060257381A1 (en) * 2003-06-27 2006-11-16 Keiya Ozawa Method for transplanting lymphohematopoietic cells into mammal
JP2019515672A (ja) * 2016-04-20 2019-06-13 フレッド ハッチンソン キャンサー リサーチ センター 免疫調整性ｉｌ２ｒ融合タンパク質およびその使用
JP2021514677A (ja) * 2018-03-02 2021-06-17 アロジーン セラピューティクス，インコーポレイテッド 誘導性キメラサイトカイン受容体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939634B2 (en) * 2004-01-27 2011-05-10 Compugen Ltd. Polynucleotides encoding polypeptides and methods using same
DK2956175T3 (da) * 2013-02-15 2017-11-27 Univ California Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
MX373687B (es) * 2013-11-21 2020-07-07 Ucl Business Ltd Célula natural (nk)
WO2016075612A1 (en) * 2014-11-12 2016-05-19 Rinat Neuroscience Corp. Inhibitory chimeric antigen receptors
EP3443002A4 (en) * 2016-04-14 2019-12-04 Bluebird Bio, Inc. SYSTEMS FOR RECOVERED CHIMERIC ANTIGEN RECEPTORS
EP4041760A4 (en) * 2019-10-08 2023-10-11 Zymeworks BC Inc. Modified extracellular domain of granulocyte colony-stimulating factor receptor (g-csfr) and cytokines binding same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08511000A (ja) * 1993-04-06 1996-11-19 フレッド ハッチンソン キャンサー リサーチ センター リンパ球におけるキメラサイトカインレセプター
JP2001501444A (ja) * 1995-11-27 2001-02-06 ミレニウム ファーマシューティカルズ インク． Ｏｂ受容体ならびに体重障害の診断および治療の方法
US20060257381A1 (en) * 2003-06-27 2006-11-16 Keiya Ozawa Method for transplanting lymphohematopoietic cells into mammal
WO2006115026A1 (ja) * 2005-04-22 2006-11-02 Japan Science And Technology Agency ヒューマニン受容体又はヒュ－マニン様ポリペプチド受容体
JP2019515672A (ja) * 2016-04-20 2019-06-13 フレッド ハッチンソン キャンサー リサーチ センター 免疫調整性ｉｌ２ｒ融合タンパク質およびその使用
JP2021514677A (ja) * 2018-03-02 2021-06-17 アロジーン セラピューティクス，インコーポレイテッド 誘導性キメラサイトカイン受容体

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DEBBIE C. KOAY ET AL., CELLULAR SIGNALLING, vol. 14, JPN6024043678, 2002, pages 239 - 247, ISSN: 0005566916 *
GERMAINE FUH ET AL., SCIENCE, vol. 256, JPN6024043681, 1992, pages 1677 - 1680, ISSN: 0005451018 *
JUNGALEE ANOUCHKA: "Implication physiopathologique de I'adaptateur LNK: mecanismes d'action et perspectives therapeutiqu", HAL OPEN SCIENCE, JPN6025013811, 2018, ISSN: 0005566920 *
MARK A GOLDSMITH ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 37, JPN6025013810, pages 21729 - 21737, ISSN: 0005566919 *
MATTHIAS ERNST ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 14, JPN6024043679, 1999, pages 9729 - 9737, ISSN: 0005566917 *
秋山 英雄: "遺伝子組換え技術による有用プラスミド構築に関する研究", 学習院大学博士論文, JPN6025013812, 2001, ISSN: 0005566921 *
長棟 輝行: "抗腫瘍活性を高めるエフェクター細胞および樹状細胞の選択的増幅法の開発", 科学研究費助成事業 ２００４年度 実績報告書, [ONLINE], JPN6024043680, 2006, ISSN: 0005566918 *

Also Published As

Publication number Publication date
EP4041893A1 (en) 2022-08-17
WO2021068068A1 (en) 2021-04-15
US20240122979A1 (en) 2024-04-18
IL291282A (en) 2022-05-01
KR20220108768A (ko) 2022-08-03
MX2022003885A (es) 2022-07-13
AU2020362554A1 (en) 2022-05-12
BR112022006782A2 (pt) 2022-09-06
JP2025163198A (ja) 2025-10-28
CA3151472A1 (en) 2021-04-15
CN114929752A (zh) 2022-08-19
EP4041893A4 (en) 2023-08-30

Similar Documents

Publication Publication Date Title
JP7479082B2 (ja) 免疫機能制御因子をコードする核酸、及びがん抗原を特異的に認識する細胞表面分子、ｉｌ－７及びｃｃｌ１９を発現する免疫担当細胞の作製方法
US20230248770A1 (en) Human leukocyte antigen restricted gamma delta t cell receptors and methods of use thereof
JP2022552949A (ja) キメラサイトカイン受容体
Alpdogan et al. IL-7 and IL-15: therapeutic cytokines for immunodeficiency
EP1814580B1 (en) Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
CN112969784A (zh) 工程化调节性t细胞
Bontkes et al. Tumor associated antigen and interleukin-12 mRNA transfected dendritic cells enhance effector function of natural killer cells and antigen specific T-cells
CA2940163C (en) Tscm cells and methods for use
CN114901684B (zh) 粒细胞集落刺激因子受体(g-csfr)的经修饰胞外结构域和结合其的细胞因子
JP2019532036A (ja) メラノーマの処置のための方法および組成物
US20240254182A1 (en) Modified granulocyte colony-stimulating factor (g-csf) and chimeric cytokine receptors binding same
CN113278652B (zh) 增加Survivin表达的CAR-T细胞并联合IL-15在制备抗肿瘤药物中的应用
Turksma et al. Increased cytotoxic capacity of tumor antigen specific human T cells after in vitro stimulation with IL21 producing dendritic cells
JP7197538B2 (ja) メラノーマの処置のための方法および組成物
CN117425679A (zh) 经修饰的粒细胞集落刺激因子(g-csf)和结合其的嵌合细胞因子受体
WO2025122569A1 (en) T cell receptor specific to kmt2a::aff1 neoantigen and use thereof in adoptive immunotherapy
EP4731648A1 (en) Constitutive cytokine receptors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220708

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220411

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250131

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250407